Advertisement

Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review

      ABSTRACT

      Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are the mainstay of treatment for hypercholesterolemia as they effectively reduce LDL-C levels and risk of atherosclerotic cardiovascular disease. Apart from hyperglycemia, dyslipidemia and HDL dysfunction are known risk factors for neuropathy in people with obesity and diabetes. Although there are case reports of statin-induced neuropathy, ad hoc analyses of clinical trials and observational studies have shown that statins may improve peripheral neuropathy. However, large randomized controlled trials and meta-analyses of cardiovascular outcome trials with statins and other lipid-lowering drugs have not reported on neuropathy outcomes. Because neuropathy was not a prespecified outcome in major cardiovascular trials, one cannot conclude whether statins or other lipid-lowering therapies increase or decrease the risk of neuropathy. The aim of this review was to assess if statins have beneficial or detrimental effects on neuropathy and whether there is a need for large well-powered interventional studies using objective neuropathy end points.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schade D
        • Shey L
        • Eaton P.
        Prescribing statins to reduce cardiovascular disease: 10 common misconceptions.
        Am J Med. 2019; 132: 897-899
        • Collins R
        • Reith C
        • Emberson J
        • Armitage J
        • Baigent C
        • Blackwell L
        • et al.
        Interpretation of the evidence for the efficacy and safety of statin therapy.
        Lancet. 2016; 388: 2532-2561
        • Durrington P.
        Hyperlidaemia: Diagnosis & Management.
        3rd ed. CRC Press, 2007
        • Runz H
        • Rietdorf J
        • Tomic I
        • de Bernard M
        • Beyreuther K
        • Pepperkok R
        • et al.
        Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells.
        J Neurosci. 2002; 22: 1679-1689
        • Al-kuraishy HM
        • Al-Gareeb AI
        • Hussein NR
        • Al-naimi MS
        • Rasheed HA
        Statins an oft-prescribed drug is implicated in peripheral neuropathy: the time to know more.
        J Pak Med Assoc. 2019; 69: s108-s112
        • Zheng J
        • Lu C.
        Oxidized LDL causes endothelial apoptosis by inhibiting mitochondrial fusion and mitochondria autophagy.
        Front Cell Dev Biol. 2020; 8
        • Vincent A
        • Hinder L
        • Pop-Busui R
        • Feldman E.
        Hyperlipidemia: a new therapeutic target for diabetic neuropathy.
        J Peripher Nerv Syst. 2009; 14: 257-267
        • Isomaa B
        • Henricsson M
        • Almgren P
        • Tuomi T
        • Taskinsen M-R
        • Groop L.
        The metabolic syndrome influences the risk of chronic complications in patients with type 2 diabetes.
        Diabetologia. 2001; 44: 1148-1154
        • Yorek MA.
        Vascular impairment of epineurial arterioles of the sciatic nerve: implications for diabetic peripheral neuropathy.
        Rev Diabet Stud. 2015; 12: 13-28
        • Malik RA
        • Newrick PG
        • Sharma AK
        • Jennings A
        • Ah-See AK
        • Mayhew TM
        • et al.
        Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy.
        Diabetologia. 1989; 32: 92-102
        • Iqbal Z
        • Bashir B
        • Ferdousi M
        • Kalteniece A
        • Alam U
        • Malik R
        • et al.
        Lipids and peripheral neuropathy.
        Curr Opin Lipidol. 2021; 32: 249-257
        • Chong PH
        • Boskovich A
        • Stevkovic N
        • Bartt RE.
        Statin-associated peripheral neuropathy: review of the literature.
        Pharmacotherapy. 2004; 24: 1194-1203
        • Stancu C
        • Sima A.
        Statins: mechanism of action and effects.
        J Cell Mol Med. 2001; 5: 378-387
        • Ward NC
        • Watts GF
        • Eckel RH.
        Statin toxicity: mechanistic insights and clinical implications.
        Circ Res. 2019; 124: 328-350
        • Sehayek E
        • Butbul E
        • Avner R
        • Levkovitz H
        • Eisenberg S.
        Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors.
        Eur J Clin Invest. 1994; 24: 173-178
        • Soran H
        • France M
        • Adam S
        • Iqbal Z
        • Ho JH
        • Durrington PN.
        Quantitative evaluation of statin effectiveness versus intolerance and strategies for management of intolerance.
        Atherosclerosis. 2020; 306: 33-40
        • Soran H
        • Adam S
        • Durrington PN.
        Optimising treatment of hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
        Atherosclerosis. 2018; 278: 135-142
        • Soran H
        • Adam S
        • Durrington PN
        Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat.
        Eur J Prevent Cardiol. 2017; 24: 76-83
        • Soran H
        • Kwok S
        • Adam S
        • Ho JH
        • Durrington PN
        Evidence for more intensive cholesterol lowering.
        Curr Opin Lipidol. 2017; 28: 291-299
        • Endo A.
        The discovery and development of HMG-CoA reductase inhibitors.
        J Lipid Res. 1992; 33: 1569-1582
        • Baigent C
        • Blackwell L
        • Emberson J
        • Holland LE
        • Reith C
        • et al.
        • Cholesterol Treatment Trialists’ (CTT) Collaborators
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,00 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Soran H
        • Schofield JD
        • Dunnington PN.
        Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.
        Eur Heart J. 2015; 36: 2975-2983
        • Bhatnagar D
        • Soran H
        • Durrington PN.
        Hypercholesterolaemia and its management.
        BMJ. 2008; 337: a993
        • Soran H
        • Liu Y
        • Adam S
        • Siahmansur T
        • Ho JH
        • Schofield JD
        • et al.
        A comparison of the effects of low- and high- dose atorvastatin on lipoprotein metabolism and inflammatory cytokines in type 2 diabetes: results from the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) randomized trial.
        J Clin Lipidol. 2018; 12: 44-55
        • Kearney PM
        • Blackwell L
        • Collins R
        • Keech A
        • Simes J
        • et al.
        • Cholesterol Treatment Trialists’ (CTT) Collaborators
        Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
        Lancet. 2008; 371: 117-125
        • Colhoun H
        • Betteridge DJ
        • Durrington P
        • Hitman G
        • Neil HA
        • Livingstone S
        • et al.
        Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
        Lancet. 2004; 364: 685-696
        • McFarland A
        • Anoopkumar-Dukie S
        • Arora D
        • Grant G
        • McDermott C
        • Perkins A
        • et al.
        Molecular mechanisms underlying the effects of statins in the central nervous system.
        Int J Molecul Sci. 2014; 15: 20607-20637
        • Mach F
        • Ray K
        • Wiklund O
        • Corsini A
        • Catapano A
        • Bruckert E
        • et al.
        Adverse effects of statin therapy: perception vs. the evidence—focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.
        Eur Heart J. 2018; 39: 2526-2539
        • Davies J
        • Delfino S
        • Feinberg C
        • Johnson M
        • Nappi V
        • Olinger J
        • et al.
        Current and emerging uses of statins in clinical therapeutics: a review.
        Lipid Insights. 2016; 9: 13-29
        • Tobert JA
        • Newman CB.
        The nocebo effect in the context of statin intolerance.
        J Clin Lipidol. 2016; 10: 739-747
        • Stroes ES
        • Thompson PD
        • Corsini A
        • Vladutiu GD
        • Raal FJ
        • Ray KK
        • et al.
        Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management.
        Eur Heart J. 2015; 36: 1012-1022
        • Adhyaru BB
        • Jacobson TA.
        Safety and efficacy of stating therapy.
        Nature Rev Cardiol. 2018; 15: 757-769
        • Gupta A
        • Thompson D
        • Whitehouse A
        • Collier T
        • Dahlof B
        • Poulter N
        • et al.
        Adverse events associate with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
        Lancet. 2017; 389: 2473-2481
        • Cohen JD
        • Brinton EA
        • Ito MK
        • Jacobson TA.
        Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survery of 10,138 current and former statin users.
        J Clin Lipidol. 2012; 6: 208-215
        • Hovingh GK
        • Gandra SR
        • McKendrick J
        • Dent R
        • Wieffer H
        • Catapano AL
        • et al.
        Identification and management of patients with statin-associated symptoms in clinical practice: a clinician survey.
        Atherosclerosis. 2016; 245: 111-117
        • Kon RH
        • Russo MW
        • Ory B
        • Mendys P
        • Simpson Jr, RJ
        Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising.
        J Clin Lipidol. 2008; 2: 51-57
        • Preiss D
        • Seshasai S
        • Welsh P
        • Murphy S
        • Ho J
        • Waters D
        • et al.
        Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
        JAMA. 2011; 305: 2556-2564
        • Sattar N
        • Preiss D
        • Murray H
        • Welsh P
        • Buckley B
        • de Craen A
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Sampson UK
        • Linton MF
        • Fazio S.
        Are statins diabetogenic?.
        Curr Opin Cardiol. 2011; 26: 342-347
        • Maki KC
        • Ridker PM
        • Brown WV
        • Grundy SM
        • Sattar N
        The Diabetes Subpanel of the National Lipid Association Expert Panel. An assessment by the Statin Diabetes Safety Taskforce: 2014 update.
        J Clin Lipidol. 2014; 8: S17-S29
        • Swerdlow DI
        • Preiss D
        • Kuchenbaecker KB
        • Holmes MV
        • Engmann JEL
        • Shah T
        • et al.
        HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
        Lancet. 2015; 385: 351-361
        • Pinal-Fernandez I
        • Casal-Dominguez M
        • Mammen AL.
        Statins: pros and cons.
        Medicina Clinica. 2018; 150: 398-402
        • Soran H
        • Ho JH
        • Durrington PN.
        Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets.
        Curr Opin Lipidol. 2018; 29: 318-326
        • Azmi S
        • Ferdousi M
        • Petropoulos IN
        • Ponirakis G
        • Alam U
        • Fadavi H
        • et al.
        Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes.
        Diabetes Care. 2015; 38: 1502-1508
        • Singleton JR
        • Smith AG
        • Russell JW
        • Feldman EL.
        Microvascular complications of impaired glucose tolerance.
        Diabetes. 2003; 52: 2867-2873
        • Asghar O
        • Petropoulos IN
        • Alam U
        • Jones W
        • Jeziorska M
        • Marshall A
        • et al.
        Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance.
        Diabetes Care. 2014; 37: 2643-2646
        • Backes JM
        • Howard PA.
        Association of HMG-CoA reductase inhibitors with neuropathy.
        Ann Pharmacother. 2003; 37: 274-278
        • Phan T
        • McLeod JG
        • Pollard JD
        • Peiris O
        • Rohan A
        • Halpern J-P.
        Peripheral neuropathy associated with simvastatin.
        J Neurol Neurosurg Psychiatry. 1995; 58: 625-628
        • Gaist D
        • Rodriquez LAG
        • Huerta C
        • Hallas J
        • Sindrup SH.
        Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?.
        Eur J Clin Pharmacol. 2001; 56: 931-933
        • Svendsen TdK
        • Hansen PN
        • Rodriguez LAG
        • Andersen L
        • Hallas J
        • Sindrup SH
        • et al.
        Statins and polyneuropathy revisited: case-control study in Denmark, 1999-2013.
        Br J Clin Pharmacol. 2017; 83: 2087-2095
        • Svendsen TdK
        • Kroigard T
        • Wirenfeldt M
        • Schroder HD
        • Bak S
        • Moller S
        • et al.
        Statin use and peripheral nerve function—a prospective follow-up study.
        Basic Clin Pharmacol Toxicol. 2019; 126: 203-211
        • Warendorf JK
        • Vrancken AFJE
        • van Ejik RPA
        • Visser NA
        • van den Berg LH
        • Notermans NC.
        Statins do not increase risk of polyneuropathy.
        Neurology. 2019; 92: e2136-e2e44
        • Hernández-Ojeda J
        • Roman-Pintos LM
        • Rodriguez-Carrizalez AD
        • Troyo-Sanroman R
        • Cardona-Munoz EG
        • Alatorre-Carranza MdP
        • et al.
        Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study.
        Diabetes Metab Syndr Obes. 2014; 7: 401-407
        • Davis TME
        • Yeap BB
        • Davis WA
        • Bruce DG.
        Lipid-Lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.
        Diabetologia. 2008; 51: 562-566
        • Pergolizzi Jr, JV
        • Manusson P
        • LeQuang JA
        • Razmi R
        • Zampogna G
        • Taylor Jr, R
        Statins and neuropathic pain: a narrative review.
        Pain Therapy. 2020; 9: 97-111
        • Kazamel M
        • Stino AM
        • Smith AG.
        Metabolic syndrome and peripheral neuropathy.
        Muscle Nerve. 2021; 63: 285-293
        • Morkavuk G
        • Leventoglu A.
        Small fiber neuropathy associated with hyperlidemia: utility of cutaneous silent periods and autonomic tests.
        Int Sch Res Notices. 2014; 579242
        • Obrosova IG
        • Ilnytska O
        • Lyzoguboc VV
        • Pavlov IA
        • Mashtalir N
        • Nadler JL
        • et al.
        High-fat diet induced neuropathy of pre-diabetes and obesity: effects of 'healthy' diet and aldose reductase inhibition.
        Diabetes. 2007; 56: 2598-2608
        • Vincent AM
        • Callaghan BC
        • Smith AL
        • Feldman EL.
        Diabetic neuropathy: cellular mechanisms as therapeutic targets.
        Nature Rev Neurol. 2011; 7: 573-583
        • Tesfaye S
        • Chaturvedi N
        • Eaton S
        • Ward J
        • Manes C
        • Ionescu-Tirgoviste C
        • et al.
        Vascular risk factors and diabetic neuropathy.
        N Engl J Med. 2005; 352: 341-350
        • Mizokami-Stout KR
        • Li Z
        • Foster NC
        • Shah V
        • Aleppo G
        • McGill JB
        • et al.
        The contemporary prevalence of diabetic neuropathy in type 1 diabetes: findings from the T1D Exchange.
        Diabetes Care. 2020; 43: 806-812
        • Smith A
        • Singleton J.
        Obesity and hyperlipidemia are risk factors for early diabetic neuropathy.
        J Diabetes Complications. 2013; 27: 436-442
        • Andersen ST
        • Witte DR
        • Fleischer J
        • Andersen H
        • Lauritzen T
        • Jørgensen ME
        • et al.
        Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark.
        Diabetes Care. 2018; 41: 2586-2594
        • Jang E-H
        • Park Y-M
        • Hur J
        • Kim M-K
        • Ko S-H
        • Baek K-H
        • et al.
        Higher levels of small dense low-density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with type 2 diabetes.
        Diabetic Med. 2013; 30: 694-701
        • Beyca HH
        • Mesci B
        • Telci Caklili O
        • Mutlu HH
        • Oguz A
        Neuropathy associated with hypertriglyceridemia in patients with metabolic syndrome.
        Acta Endocrinologica. 2016; 12: 26-29
        • Christensen DH
        • Knudsen SørT
        • Gylfadottir SS
        • Christensen LB
        • Nielsen JS
        • Beck-Nielsen H
        • et al.
        Metabolic factors, lifestyle habits, and possible polyneuropathy in early type 2 diabetes: a nationwide study of 5,248 patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort.
        Diabetes Care. 2020; 43: 1266-1275
        • Fadavi H
        • Tavakoli M
        • Foden P
        • Ferdousi M
        • Petropoulos IN
        • Jeziorska M
        • et al.
        Explanations for less small fibre neuropathy in South Asian versus European subjects with type 2 diabetes in the UK.
        Diabetes Metab Res Rev. 2018; 34: e3044
        • Azmi S
        • Ferdousi M
        • Liu Y
        • Adam S
        • Siahmansur T
        • Ponirakis G
        • et al.
        The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity.
        Scientific Rep. 2021; : 11
        • Cai Z
        • Yang Y
        • Zhang J
        A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy.
        Sci Rep. 2021; 11: 499
        • Andersen ST
        • Grosen K
        • Tankisi H
        • Charles M
        • Andersen NT
        • Andersen H
        • et al.
        Corneal confocal microscopy as a tool for detecting diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes: ADDITION-Denmark.
        J Diabetes Complications. 2018; 32: 1153-1159
        • Adam S
        • Azmi S
        • Ho JH
        • Liu Y
        • Ferdousi M
        • Siahmansur T
        • et al.
        Improvements in diabetic neuropathy and nephropathy after bariatric surgery: a prospective cohort study.
        Obes Surg. 2021; 31: 554-563
        • Azmi S
        • Ferdousi M
        • Liu Y
        • Adam S
        • Iqbal Z
        • Dhage S
        • et al.
        Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity.
        Int J Obes (Lond). 2021; 45: 631-638
        • Perkins BA
        • Dholasania A
        • Buchanan RA
        • Bril V.
        Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis.
        Diabetic Med. 2010; 27: 1271-1279
        • Kassem HS
        • Azar ST
        • Zantout MS
        • Sawaya RA.
        Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients.
        Neuro Endocrinol Lett. 2005; 26: 775-779
        • Al-Shareefi SJ
        • El-Yassin HD
        • Dawoud A-RH
        The role of hyperlidemia on nerve conduction.
        J Fac Med Baghdad. 2008; 50: 105-109
        • Newman CB
        • Preiss D
        • Tobert JA
        • Jacobson TA
        • Page 2nd, RL
        • Goldstein LB
        • et al.
        Statin safety and associated adverse events: a scientific statement from the American Heart Association.
        Arterioscler Thromb Vasc Biol. 2019; 39: e38-e81
        • Otruba P
        • Kanovsky P
        • Hlustik P.
        Treatment with statins and peripheral neuropathy: results of 36-months a prospective clinical and neurophysiological follow-up.
        Neuroendocrinol Lett. 2011; 32: 101-103
        • Hammad MA
        • Sulaiman SAS
        • Alghamdi S
        • Mangi AA
        • Aziz NA
        • Noor DAM.
        Statins-related peripheral neuropathy among diabetic patients.
        Diabetes Metab Syndr Clin Res Rev. 2020; 14: 341-346
        • Corrao G
        • Zambon A
        • Bertu L
        • Botteri E
        • Leoni O
        • Contiero P.
        lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
        J Epidemiol Community Health. 2004; 58: 1047-1051
        • Tierney EF
        • Thurman DJ
        • Beckles GL
        • Cadwell BL.
        Association of statin use with peripheral neuropathy in the US population 40 years of age or older.
        J Diabetes. 2013; 5: 207-215
        • Nielsen SF
        • Nordestgaard BG.
        Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study.
        Lancet Diabetes Endocrinol. 2014; 2: 894-900
        • Macedo AF
        • Taylor FC
        • Casas JP
        • Adler A
        • Prieto-Merino D
        • Ebrahim S.
        Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.
        BMC Med. 2014; : 12
        • Kristensen FP
        • Christensen DH
        • Callaghan BC
        • Kahlert J
        • Knudsen SrT
        • Sindrup SørH
        • et al.
        Statin therapy and risk of polyneuropathy in type 2 diabetes: a Danish cohort study.
        Diabetes Care. 2020; 43: 2945-2952
        • Tuccori M
        • Montagnani S
        • Mantarro S
        • Capogrosso-Sansone A
        • Ruggiero E
        • Saporiti A
        • et al.
        Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.
        CNS Drugs. 2014; 28: 249-272
        • Hyyppä MT
        • Kronholm E
        • Virtanen A
        • Leino A
        • Jula A
        Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial.
        Psychoneuroendocrinology. 2003; 28: 181-194
        • Stewart R
        • Sharples K
        • North F
        • Menkes DB
        • Baker J
        • Simes J.
        Long-term association of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin.
        Arch Intern Med. 2000; 160: 3144-3152
        • Emad M
        • Arjmand H
        • Farpour HR
        • Kardeh B.
        Lipid-lowering drugs (statins) and peripheral neuropathy.
        Electronic Physician. 2018; 10: 6527-6533
        • Golomb BA
        • Evans MA.
        Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism.
        Am J Cardiovasc Drugs. 2008; 8: 373-418
        • Wang Q
        • Yan J
        • Chen X
        • Li J
        • Yang Y
        • Weng J
        • et al.
        Statins: multiple neuroprotective mechanisms in neurodegenerative diseases.
        Experimental Neurol. 2011; 230: 27-34
        • Berger C
        • Xia F
        • Maurer MH
        • Schwab S.
        Neuroprotection by pravastatin in acute ischemic stroke in rats.
        Brain Res Rev. 2008; 58: 48-56
        • Torrandell-Haro G
        • Branigan GL
        • Vitali F
        • Geifman N
        • Zissimopoulos JM
        Brinton RD. Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases.
        Trans Res Clin Intervent. 2020; 6: e12108
        • Wong WB
        • Lin VW
        • Boudreau D
        • Devine EB.
        Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding.
        Pharmacoepidemiol Drug Saf. 2012; 22: 345-358
        • Posvar EL
        • Radulovic LL
        • Cilla Jr, DD
        • Whitfield LR
        • Sedman AJ
        Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.
        J Clin Pharmacol. 1996; 36: 728-731
        • Schultz BG
        • Patten DK
        • Berlau DJ.
        The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms.
        Transl Neurodegener. 2018; 7: 1-11
        • Wagstaff LR
        • Mitton MW
        • Arvik B
        • Doraiswamy P.
        Statin-associated memory loss: analysis of 60 case reports and review of the literature.
        Pharmacotherapy. 2003; 23: 871-880
        • Toth PP
        • Banach M.
        Statins: then and now.
        Methodist DeBakey Cardiovasc J. 2019; 15: 23-31
        • Cholesterol Treatment Trialists’ (CTT) Collaborators
        The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
        Lancet. 2012; 380: 581-590
        • Perez-Matos MC
        • Morales-Alvarez MC
        • Mendivil CO
        Lipids: a suitable therapeutic target in diabetic neuropathy?.
        J Diabetes Res. 2017; 2017: 1-9
        • Cho YR
        • Lim JH
        • Kim MY
        • Kim TW
        • Hong BY
        • Kim Y-S
        • et al.
        Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice.
        PLoS ONE. 2014; 9: 1-12
        • Ferdousi M
        • Kalteniece A
        • Azmi S
        • Petropoulos IN
        • Ponirakis G
        • Alam U
        • et al.
        Diagnosis of neuropathy and risk factors for corneal nerve loss in type 1 and type 2 diabetes: a corneal confocal microscopy study.
        Diabetes Care. 2021; 44: 150-156
        • Wiggin TD
        • Sullivan KA
        • Pop-Busui R
        • Amato A
        • Sima AAF
        • Feldman EL.
        Elevated triglycerides correlate with progression of diabetic neuropathy.
        Diabetes. 2009; 58 (1634-0)
        • Corcia P
        • De Toffol B
        • Hommet C
        • Autret A
        Jonville-Bera A. Severe toxic neuropathy due to fibrates.
        J Neurol Neurosurg Psychiatry. 1999; 66: 410
        • Bergeron N
        • Phan BAP
        • Ding Y
        • Fong A
        • Krauss RM.
        Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
        Circulation. 2015; 132: 1648-1666
        • Abifadel M
        • Varret M
        • Rabès J-P
        • Allard D
        • Ouguerram K
        • Devillers M
        • et al.
        Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
        Nat Genet. 2003; 34: 154-156
        • Ridker PM
        • Revkin J
        • Amarenco P
        • Brunell R
        • Curto M
        • Civeira F
        • et al.
        Cardiovascular efficacy and safety of bococizumab in high-risk patients.
        N Engl J Med. 2017; 376: 1527-1539
        • Sabatine MS
        • Giugliano RP
        • Keech AC
        • Honarpour N
        • Wiviott SD
        • Murphy SA
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Schwartz GG
        • Steg G
        • Szarek M
        • Bhatt DL.
        Alirocumab and cardiovascular outcomes after acute coronary syndrome.
        N Engl J Med. 2018; 379: 2097-2107
        • Squizzato A
        • Suter MB
        • Nerone M
        • Giugliano RP
        • Dentali F
        • Maresca AM
        • et al.
        PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and meta-analysis.
        Intern Emerg Med. 2017; 12: 1043-1053
        • Levenson AE
        • Shah AS
        • Khoury PR
        • Kimball TR
        • Urbina EM
        • de Ferranti SD
        • et al.
        Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women.
        Pediatr Diabetes. 2017; 18: 755-760
        • Levenson AE
        • Wadwa RP
        • Shah AS
        • Khoury PR
        • Kimball TR
        • Urbina EM
        • et al.
        PCSK9 is increased in youth with type 1 diabetes.
        Diabetes Care. 2017; 40: e85-ee7
        • Levenson AE
        • Milliren CE
        • Biddinger SB
        • Ebbeling CB
        • Feldman HA
        • Ludwig DS
        • et al.
        Calorically restricted diets decrease PCSK9 in overweight adolescents.
        Nutr Metab Cardiovasc Dis. 2017; 27: 342-349
        • Bek T
        • Al-Mashhadi RH
        • Misfeldt M
        • Riis-Vestergaard MJ
        • Bentzon JF
        • Pedersen SM
        Relaxation of porcine retinal arterioles exposed to hypercholesterolemia in vivo is modified by hepatic LDL-receptor deficiency and diabetes mellitus.
        Exp Eye Res. 2013; 115: 79-86
        • Do HT
        • Bruelle C
        • Pham DD
        • Jauhiainen M
        • Eriksson O
        • Korhonen LT
        • et al.
        Nerve growth factor (NGF) and pro-NGF increase low-density lipoprotein (LDL) receptors in neuronal cells partly by different mechanisms: role of LDL in neurite outgrowth.
        J Neurochem. 2016; 136: 306-315
        • Kysenius K
        • Huttunen HJ.
        Stress-induced upregulation of VLDL receptor alters Wnt-signaling in neurons.
        Exp Cell Res. 2016; 340: 238-247
        • Zhao XS
        • Wu Q
        • Peng J
        • Pan LH
        • Ren Z
        • Liu HT
        • et al.
        Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(-/-) mice may be associated with increased PCSK9 expression.
        Mol Med Rep. 2017; 15: 712-718
        • Lipinski MJ
        • Benedetto U
        • Escarcega RO
        • Biondi-Zoccai G
        • Lhermusier T
        • Baker NC
        • et al.
        The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.
        Eur Heart J. 2016; 37: 536-545
        • Robinson JG
        • Farnier M
        • Krempf M
        • Bergeron J
        • Luc G
        • Averna M
        • et al.
        Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
        N Engl J Med. 2015; 372: 1489-1499
        • Giugliano RP
        • Mach F
        • Zavitz K
        • Kurtz C
        • Schneider J
        • Wang H
        • et al.
        Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy—a cognitive study of patients enrolled in the FOURIER trial.
        Clin Cardiol. 2017; 40: 59-65
      1. FDA advises of adverse effects from new cholesterol drugs [Available from: http://www.wsj.com/articles/SB10001424052702304732804579425612487904436] 2022.

        • Ponirakis G
        • Al Hamad H
        • Sankaranarayanan A
        • Khan A
        • Chandran M
        • Ramadan M
        • et al.
        Association of corneal nerve fiber measures with cognitive function in dementia.
        Ann Clin Transl Neurol. 2019; 6: 689-697
        • Al-Janahi E
        • Ponirakis G
        • Al Hamad H
        • Vattoth S
        • Elsotouhy A
        • Petropoulos IN
        • et al.
        Corneal nerve and brain imaging in mild cognitive impairment and dementia.
        J Alzheimers Dis. 2020; 77: 1533-1543
        • Soran H
        • Kalteniece A
        • Ferdousi M
        • Iqbal Z
        • Liu Y
        • Baptist M
        • et al.
        PCSK9 monoclonal antibody treatment promotes small fibre regeneration in heterozygous familial hypercholesterolemia.
        Atherosclerosis. 2020; 315: e215